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A randomized, double-blind study comparing the efficacy and 
safety of trazodone once-a-day and venlafaxine extended-
release for the treatment of patients with major depressive 
disorder
Andrea Fagiolinia, Umberto Albertb, Laura Ferrandoc, Erik Hermand,  
Cosmina Munteane, Eva Pálováf, Agnese Cattaneog,  
Alessandro Comandinig, Giorgio Di Datog, Giorgio Di Loretog,  
Luisa Olivierig, Enrica Salvatorig, Serena Tongianig and Siegfried Kasperh       
This double-blind, randomized study evaluated the 
efficacy and safety of trazodone OAD (once-a-day) in 
comparison with venlafaxine XR (extended-release) in 
324 patients (166 trazodone and 158 venlafaxine) with 
major depressive disorder (MDD). The primary efficacy 
endpoint was the mean change from baseline in the 
17-item Hamilton Depression Rating Scale (HAM-D) at 
week 8. Both treatments were effective in reducing the 
HAM-D-17 total score at week 8 vs. baseline (intent-to-
treat: trazodone –12.9, venlafaxine –14.7; per protocol: 
trazodone –15.4, venlafaxine –16.4). Patients in the 
venlafaxine group achieved better results after 8 weeks, 
whereas the trazodone group achieved a statistically 
significant reduction in HAM-D-17 following only 7 days of 
treatment. The most frequent adverse events (AEs) were 
dizziness and somnolence in the trazodone group, and 
nausea and headache in the venlafaxine group. Most AEs 
were mild-to-moderate in severity. This study confirmed 
that both venlafaxine XR and trazodone OAD may 
represent a valid treatment option for patients with MDD. 
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Introduction
Major depressive disorder (MDD) is a common psychiat-
ric condition characterized by depressed mood combined 
with psychological and vegetative changes, such as sleep 
and/or appetite disturbances, fatigue, loss of motivation, 
feelings of guilt and despair, difficulties in maintaining 
mental focus, and suicidal thinking and behavior (Kelliny 
et al., 2015). The WHO estimates that major depression 
affects approximately 350 million people worldwide and 
is one of the leading causes of global disability (Marcus 
et al., 2012). According to recent projections, MDD will 
rise to be among the top three disabling conditions in the 
world by 2030, together with HIV/AIDS and ischemic 
heart disease (Mathers and Loncar, 2006).
According to the current guidelines, a successful treat-
ment for MDD includes the achievement of sympto-
matic remission and functional recovery (Davidson, 
2010). Nevertheless, evidence from trials and clinical 
practice has shown that the efficacy of antidepressants is 
suboptimal. Indeed, approximately 30–40% of patients 
achieve full remission after a single course of treatment, 
and 30%, although achieving a clinically significant 
response, show residual symptoms with increased risk of 
relapse and affecting the social functioning (Katona and 
Katona, 2014).
However, antidepressants still play a crucial role in the 
treatment of MDD, provided that adherence to medi-
cations is guaranteed. Indeed, low adherence is widely 
recognized as one of the main reasons for treatment fail-
ure and is associated with an increased risk of relapse and 
recurrence (Ho et al., 2016). Evidence from clinical studies 
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show that adherence rates are generally low in patients 
with MDD, in some cases as low as 50% (Melartin et al., 
2005; Cantrell et al., 2006; Akincigil et al., 2007; Alekhya et 
al., 2015a; Alekhya et al., 2015b). This is mainly because 
mood disorders impairing cognitive focus, energy, and 
motivation might affect the willingness and ability of 
patients to maintain the treatment (DiMatteo et al., 2000). 
The occurrence of treatment-related side effects, such as 
weight gain, sexual dysfunction, nausea, headache, and 
sleep disturbances, is also common and may influence 
treatment adherence.
In this context, a simplified daily regimen represents a 
clinical advantage, and it may be practical to increase 
treatment success rates in depression (Yildiz et al., 2004). 
In fact, it is a rule that the fewer the daily doses, the bet-
ter the compliance (Claxton et al., 2001). The American 
Psychiatric Association practice guidelines for the treat-
ment of patients with MDD report that most clinicians 
prefer products with once-daily dosing, which may be less 
often associated with withdrawal symptoms (Gelenberg 
et al., 2010). Premature discontinuation of medication is 
usually associated with a poorer outcome in the treat-
ment of mood disorders. It has been observed in clinical 
practice that adherence, simplicity, and efficacy usually 
go together (De las Cuevas et al., 2014).
Trazodone hydrochloride, a triazolopyridine derivative 
antidepressant drug acting through 5-HT receptors and 
inhibiting the 5-HT transporter, is the first member of 
the serotonin antagonist and reuptake inhibitor (SARI) 
class (Stahl, 2009). Trazodone is a multimodal antidepres-
sant (Bortolotto et al., 2017); it binds with high affinity to 
serotonin 5-HT
2A
 receptors, where it acts as an antago-
nist, and has moderate affinity for the 5-HT transporter 
(Stahl, 2009). It also shows activity at 5-HT
1A
 and 5-HT
2C
 
receptors, acting as a weak agonist and an antagonist, 
respectively (Stahl, 2009; Ghanbari et al., 2010). Due to its 
dose-dependent pharmacological actions, trazodone has 
been also defined as ‘multifunctional’, exerting hypnotic 
actions by blocking 5HT
2A
 and α1 adrenergic receptors at 
low doses. Its antidepressant actions are instead achieved 
by acting at 5-HT receptors with high affinity and by 
blocking serotonin transporter (SERT) at higher doses 
(Stahl, 2009).
Trazodone was compared to several other antidepres-
sants, including tricyclics, selective serotonin reuptake 
inhibitors, and serotonin-norepinephrine reuptake inhib-
itors. Overall, it was shown to be an effective and well-tol-
erated antidepressant (Fagiolini et al., 2012).
A new controlled release formulation of trazodone, allow-
ing a once-a-day administration due to the use of the 
Contramid technology, was developed with the aim of 
enhancing treatment compliance and of reducing both 
the plasma peak concentration and dosing frequency. The 
pharmacokinetic profile of trazodone OAD (once-a-day) 
is characterized by a slow increase of plasma level with a 
single low and delayed peak followed by a slow decline 
in plasma concentration. This is an advantage of the new 
formulation, since high trazodone peak plasma levels may 
be associated with the occurrence of adverse effects, such 
as somnolence or hypotension, especially during the first 
weeks of treatment. These adverse effects might limit 
the treatment tolerability and compliance in patients 
with depression (Fagiolini et al., 2012).
After a 6-week treatment period, a mean daily dose of 
trazodone OAD 310 mg was significantly more effective 
than placebo in a randomized, double-blind study per-
formed in 412 patients with MDD (Sheehan et al., 2009b). 
Compared to placebo, the antidepressant effect of trazo-
done OAD was significant as measured by the Hamilton 
Depression Rating Scale (HAM-D-17) starting from the 
first week of treatment and was maintained throughout 
all study visits (Sheehan et al., 2009b).
The aim of the present study is to compare the efficacy 
and safety of trazodone OAD with that of venlafaxine XR 
(extended-release).
Materials and methods
Study design
This was a randomized, active-controlled, double-blind, 
parallel-group study (ClinicalTrials.gov Identifier: 
NCT02086929) (Supplementary Fig. 1, Supplemental 
digital content 1, http://links.lww.com/ICP/A70).
The study was performed between December 2012 and 
April 2014. Patients were enrolled in 31 study centers 
across Europe (two in Austria, nine in the Czech Republic, 
six in Italy, seven in Romania, six in Slovakia, and one in 
Spain). The study was conducted in compliance with the 
International Conference on Harmonization Guidelines 
on General Considerations for Clinical Trials and the 
Declaration of Helsinki as adopted by the 18th World 
Medical Association (WMA) General Assembly in 1964 
and with subsequent revisions. All patients provided 
written informed consent. Written approval from all rel-
evant Review Boards/Ethics Committees was obtained 
before the commencement of the study, and the study 
sponsor was compliant with the National Drug Agency 
requirements of each country involved in the study. The 
trial was performed in compliance with the Good Clinical 
Practice guidelines.
A total of 10 visits were scheduled: one in the Pretreatment 
Phase and nine in the double-blind Treatment Phase. 
Efficacy and safety evaluations occurred at Visit 2 (base-
line), Visit 3 (7 days post-randomization; D7), Visit 4 
(D21), Visit 6 (D35), and Visit 9 (D56). Patients receiving 
increased dosages at the scheduled visits (Visit 4 and Visit 
6) were strictly monitored for safety with further visits at 
Day 28, 42, 49 (Visits 5, 7, 8, respectively).
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During the pretreatment phase, patients signed the 
informed consent form and underwent initial screen-
ing. Potential candidates were instructed to discontinue 
antidepressants or prohibited medications for a wash-out 
period specific to allow a taper schedule based on five 
elimination half-lives of the medication used. On the last 
day of the pretreatment phase, patients were evaluated 
for the final eligibility, and those qualified were randomly 
allocated to trazodone OAD 300 mg/day (1 week of taper-
ing with trazodone OAD 150 mg/day) or to venlafaxine 
XR 75 mg/day once daily, and treated for 8 weeks.
After 3 and 5 weeks of treatment, the dose was increased 
(in increments of 75 mg/day) up to 225 mg/day for venla-
faxine XR and 450 mg/day for trazodone OAD in nonre-
sponding patients. If symptoms or adverse events (AEs) 
became intolerable for the patient, dose adjustments 
were attempted after one week of dose increase.
Patients defined as responders at the final visit could 
continue treatment with the respective formulations cur-
rently available on the market. Patients not responding to 
treatment at the final visit tapered the study medication 
over 1–3 weeks according to the maximum dose reached 
during the study. These patients were monitored for 
safety throughout the tapering period (Visit 10).
If a patient discontinued early, he/she was asked to return 
to the clinic for the treatment early termination visit 
(TETV) as soon as possible, but no later than 1 week 
after discontinuation. All efficacy and safety evaluations 
were performed at the TETV.
If the treatment was judged unsuccessful and/or the tol-
erability unsatisfactory after dose adjustments, patients 
were discontinued from the study by the investigator and 
were started on an appropriate antidepressant therapy.
Inclusion and exclusion criteria
Male and female outpatients (18–75 years) who met 
the Diagnostic and Statistical Manual of Mental Disorders, 
4th edition (DSM)-IV criteria for MDD on the basis 
of the Mini International Neuropsychiatric Interview 
and 17-item HAM-D score ≥ 18 at both screening and 
baseline visits, together with a decrease not >20% 
between screening and baseline were eligible for inclu-
sion. Patients had symptoms of depression for ≥1 month 
before screening (Visit 1) and were legally capable of giv-
ing written informed consent to participate in the study. 
Women of childbearing potential had to agree not to 
start a pregnancy from the time of signing the informed 
consent up to 30 days after the last administration of the 
investigational product.
Exclusion criteria included the following: any experi-
mental psychotropic or central nervous system (CNS) 
treatment within the past 60 days; known hypersensitiv-
ity to venlafaxine or trazodone or their excipients; use of 
venlafaxine or trazodone within the previous 6 months; 
acute, or chronic, or recurrent medical conditions that 
might affect/jeopardize the study results; significant liver 
or renal disease; myocardial infarction within 6 months 
of the start of double-blind treatment; history of risk fac-
tors for Torsade de Pointes; clinically relevant laboratory 
values of electrolytes outside of the normal range; con-
comitant treatment with drugs known for QT prolonga-
tion, or with drugs producing hypokalaemia, or diuretics; 
QTcF interval >450 ms at the screening ECG. Patients 
with a history of major depression resistant to medical 
treatments, at acute risk of suicide (HAM-D, criterion 3 
with a value ≥3), with a history of seizure events, alcohol 
or psychoactive substance abuse or addiction during the 
last year, or a positive urine drug screen for CNS-active 
drugs at screening (Visit 1) were also excluded. The pres-
ence of any primary psychiatric disorder other than major 
depression, history or presence of bipolar disorder, any 
psychotic disorder, or a mental disorder due to general 
medical conditions, use of antipsychotic drugs within 
2 months before the baseline visit (Visit 2), use of any 
anxiolytic or sedative-hypnotic drug within 7 days before 
the baseline visit and during the study (except stable 
low doses of benzodiazepines for insomnia), use of any 
psychotropic drug or CNS-active substance within 7 days 
before the baseline visit, or the use of any nonpsycho-
tropic drug with psychotropic effects within 7 days before 
the baseline visit (unless a stable dose of the drug had 
been maintained for at least 1 month; 3 months for thyroid 
or hormonal medications) were not allowed. Pregnancy, 
lactation; electroconvulsive therapy within 30 days 
before the screening visit, concomitant treatment with 
cytochrome P450 3A4 (CYP3A4) inhibitors, hyperthy-
roidism, start or discontinuation of psychotherapy within 
6 weeks before screening; clinically significant abnormal-
ities on physical examination, vital signs, ECG, laboratory 
tests at the screening visit, treated or untreated supine 
systolic blood pressure > 160 mmHg or supine diastolic 
blood pressure > 90 mmHg at screening or baseline, ina-
bility to comply with the treatment program, or a relevant 
relationship to the investigator or his/her deputies were 
additional exclusion criteria. (for full inclusion/exclusion 
criteria, see Supplementary Appendix 1, Supplemental 
digital content 2, http://links.lww.com/ICP/A71).
Randomization and blinding
Patients were automatically assigned an identification 
number by an Interactive Web Response System (IWRS) 
at the screening assessment (Visit 1). At the end of the 
pretreatment phase, patients meeting the eligibility cri-
teria were randomized to trazodone OAD or venlafaxine 
XR by the IWRS system. Neither the investigators nor 
the patients were aware of the treatment assigned. To 
maintain the blinding conditions of the study, trazodone 
OAD tablets and venlafaxine XR capsules were inserted 
into capsules having an identical appearance.
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Efficacy and safety measures
The primary study endpoint for clinical efficacy was 
the mean change from baseline in HAM-D score at the 
final visit. Secondary study endpoints were as follows: (i) 
mean change from baseline in the Montgomery-Asberg 
Depression Rating Scale (MADRS) score at the final 
visit; (ii) Clinical Global Impression-Severity of Illness 
(CGI-S) and Clinical Global Impression-Global improve-
ment (CGI-G) at Visit 9 (D56); (iii) rate of responders 
(defined as patients with a 50% decrease with respect to 
baseline on the HAM-D score at the final visit), (iv) rate 
of remitters (defined as patients with HAM-D score ≤ 7 
at the final visit); (v) comparative safety and tolerability 
of trazodone OAD vs. venlafaxine XR.
Statistical analysis
Three study populations were defined for statistical anal-
ysis: the intention-to-treat (ITT) population defined as 
all randomized patients who took at least one dose of 
study medication, and having a baseline and at least one 
post-baseline HAM-D-17 total score assessment; the 
per-protocol (PP) population defined as all randomized 
patients who had no major protocol violations, completed 
the study period (from V1 to V9) and had a 17-items 
HAM-D rating at the end of the study period (V9) and 
the Safety Population, defined as all patients who took at 
least one dose of the study medication.
The safety population was used for the analysis of safety 
parameters. The ITT and PP populations were used 
for the analysis of efficacy parameters as, in a noninfe-
riority trial, the ITT and PP sets have equal importance 
(Committee for Proprietary Medicinal Products, 1998, 
2000).
Significance tests (two-sided) were performed at an alpha 
level of 5%. Secondary and other analyses were support-
ive in nature. Therefore, no adjustment for multiplicity 
was planned. Efficacy parameters were analyzed on the 
ITT population using the last observation carried for-
ward imputation scheme for missing data.
The primary efficacy end-point of the study, the demon-
stration of the noninferiority of trazodone OAD vs. ven-
lafaxine XR evaluated as change from baseline at Visit 9 
on the 17-items HAM-D total score, was analyzed by an 
analysis of covariance (ANCOVA) model with baseline 
as covariate and treatment and pooled centers as sources 
of variation. The noninferiority was fulfilled if the upper 
limit of the two-sided 95% confidence interval (CI) for 
the difference between treatments did not exceed the 
threshold of 3, representing the maximum difference 
of no clinical relevance (Sauer et al., 2003). The change 
from baseline at each postbaseline visit of the HAM-D 
total score, of the HAM-D factors (anxiety/somatization, 
cognitive disturbance, retardation, sleep disturbance) and 
of the MADRS total score were analyzed by the same 
ANCOVA model [or analysis of variance (ANOVA) if 
the statistical assumptions underlying the ANCOVA 
were not satisfied]. CGI-S and CGI-G were compared 
between groups using the Cochran-Mantel-Haenszel 
test stratified by pooled sites. Treatment groups were 
also evaluated treating the responses as continuous, and 
applying the ANCOVA or ANOVA model. Responders 
and remitters were compared between treatment groups 
by a Cochran-Mantel-Haenszel test at each visit.
AEs were coded according to the Medical Dictionary for 
Regulatory Activities (MedDRA) dictionary ver. 15.1. 
AEs were classified as AEs started on or after the first 
study medication administration date, and AEs started 
before the first study medication administration date. 
Summaries of AEs started on or after the first study med-
ication administration were presented as counts and per-
centages based on the number of patients exposed and 
compared by a Chi-square test or Fisher’s exact test. 
Listing of pretreatment and during treatment AEs were 
provided by treatment group displaying the description 
reported by the Investigator, the preferred term and the 
system organ class. Serious AEs (SAEs), other significant 
AEs, and deaths were listed and discussed with patient 
narratives. Separate listings were provided for pretreat-
ment SAEs and SAEs that emerged during the adminis-
tration of study medication.
Each laboratory test was presented by descriptive sta-
tistics per treatment group, available visits, and change 
from screening. Shift tables were calculated on the basis 
of Investigators’ assessment (normal, altered but not 
clinically significant, altered and clinically significant). 
Pregnancy tests were listed. Descriptive statistics were 
presented by treatment group for vital signs and body 
weight at each visit and on the change from baseline; 95% 
CIs were also provided. The number and percentage of 
patients with QTcF values higher than 450 ms or showing 
prolongation higher than 60 ms at any visit were provided 
and compared by a Chi-Square test or Fisher’s exact test. 
The number and percentage of patients with an abnormal 
ECG assessed as clinically significant by the investigator 
were provided for each treatment group at each visit.
The number and percentage of patients showing changes 
in the ECG evaluations with respect to the screening 
(from normal to abnormal) were provided for each treat-
ment group at each visit.
Descriptive statistics on HR, RR, PR, QRS, QT, QTcB, 
and QTcF were provided by treatment group at each 
available visit and on the changes from screening. 
Treatment group comparisons were performed by an 
ANOVA model at each visit. Changes from screening in 
the physical examination were reported.
Results
Figure 1 shows the disposition of patients throughout the 
course of the study.
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Baseline characteristics
Patients enrolled in this study were significantly ill (mod-
erate-to-severe depression), as measured by validated 
clinical inventories. There were no clinically relevant 
or statistically significant differences between the treat-
ment groups in patient demographics or clinical charac-
teristics at baseline in all populations analyzed. Among 
the patients of the Safety population, 99.1% were White, 
the majority of patients (67.5%) had not had previous 
episodes of depression necessitating hospitalization, and 
most patients (97.5%) had no other previous symptoms 
of other psychiatric illnesses. Baseline demographic and 
clinical characteristics of the Safety population are pre-
sented in Table 1.
The mean baseline severity of illness measured with 
HAM-D-17 total score was at least moderate for both 
ITT and PP populations (ITT: trazodone OAD 23.7 
± 3.42, venlafaxine XR 23.8 ± 3.93; PP: trazodone OAD 
23.9 ± 3.41, venlafaxine XR 24.1 ± 4.02). The baseline 
mean MADRS score was consistent with the HAM-D-17 
total score. Approximately, half (52.2%) of patients were 
assessed by CGI-S as at least moderately mentally ill.
Study medication
A total of 324 patients (166 in the trazodone OAD group 
and 158 in the venlafaxine XR group) were randomized, 
and 321 received at least one dose of the allocated treat-
ment (165 trazodone and 156 venlafaxine). At the end of 
the treatment period, 77.6% of patients in the trazodone 
Fig. 1
Patient disposition throughout the study.
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OAD group received a dosage of 300 mg, while in the 
venlafaxine XR group 90.4% of the patients received a 
dosage of 75 mg. The mean ± SD daily dose administered 
during the study was 311.4 (48.72) mg for trazodone and 
84.1 (29.93) mg for venlafaxine XR.
The ITT population consisted of 314 patients (162 tra-
zodone and 152 venlafaxine) who took at least one dose 
of the study medication and had a baseline and at least 
one post-baseline 17-items HAM-D total score assess-
ment. The PP population consisted of 249 patients (122 
trazodone and 127 venlafaxine) who completed the study 
period and had the 17-items HAM-D rating at the final 
visit without major protocol violations.
Efficacy
Primary efficacy endpoint
Both treatments showed good efficacy in terms of reduc-
tion of mean ± SD HAM-D-17 total score at the final visit 
compared to baseline (Fig.  2) (ITT: trazodone –12.9 ± 
6.82, venlafaxine –14.7 ± 6.56; PP: trazodone –15.4 ± 5.32, 
venlafaxine –16.4 ± 5.39). The difference between treat-
ments was on average 1.6 with the 95% CI ranging from 
0.4 to 2.9 in the ITT population (P = 0.010) and 1.1 with 
the 95% CI ranging from –0.0 to 2.2 in the PP population 
(P = 0.056). A statistically significant difference in favor of 
venlafaxine XR was detected in the ITT population after 
8 weeks, whereas no difference was detected in the PP 
population, which represents the study population with 
a higher level of compliance with the study procedure.
The severity of depression in both groups decreased 
from moderate to mild, based on the mean HAM-D-17 
total score at the final visit (ITT: trazodone 10.8 ± 6.49, 
venlafaxine 9.1 ± 6.00; PP: trazodone 8.5 ± 4.97, venlafax-
ine 7.7 ± 5.07). Once again, the PP population showed, 
in both groups, the best performance in terms of efficacy 
outcomes.
Secondary efficacy endpoints
Trazodone OAD showed an early onset of action com-
pared to venlafaxine XR. Indeed, a significantly higher 
reduction in the mean HAM-D-17 score was observed in 
the trazodone OAD group after only 7 days of treatment. 
This difference was statistically significant in both the 
Table 1 Baseline characteristics of patients
Characteristics Trazodone OAD (n = 165) Venlafaxine XR (n = 156) Overall (n = 321)
Age [mean (SD)], (years) 47.8 (11.38) 47.9 (11.41) 47.8 (11.37)
Female [n (%)] 120 (72.7) 121 (77.6) 241 (75.1)
Weight [mean (SD)], (kg) 72.7 (15.44) 73.5 (15.45) 73.1 (15.43)
Height [mean (SD)], (cm) 167.4 (8.55) 167.3 (8.16) 167.3 (8.35)
MDD history    
 Previous symptoms [n (%)] 152 (92.1) 140 (89.7) 292 (91.0)
 Age at first appearance [mean (SD)], (years) 41.5 (12.02) 42.1 (12.48) 41.8 (12.22)
 Duration of current episode [mean (SD)], (months) 2.9 (3.01) 2.9 (2.76) 2.9 (2.88)
Previous CNS medications [n (%)], (patients) 55 (33.3) 53 (34.0) 108 (33.6)
HAM-D-17 total score* [mean (SD)]    
 ITT population 23.7 (3.42) 23.8 (3.93) 23.7 (3.67)
 PP population 23.9 (3.41) 24.1 (4.02) 24.0 (3.73)
MADRS total score* [mean (SD)]    
 ITT population 27.1 (4.46) 27.1 (4.56) 27.1 (4.50)
 PP population 26.7 (4.03) 27.2 (4.53) 27.0 (4.29)
With the exception of HAM-D and MADRS scores, data are for the safety population.
ITT, intention-to-treat; HAM-D-17, 17-item Hamilton Depression Rating Scale; MADRS, Montgomery-Asberg Depression Rating Scale; MDD, major depressive disorder; 
OAD, once-a-day; PP, per-protocol; XR, extended-release.
*n = 165, n = 152 and n = 314 (ITT) and n = 162, n = 152 and n = 314 (PP) for Trazodone OAD, Venlafaxine XR and overall patient population, respectively.
Fig. 2
Mean total score over time in the ITT/LOCF population (a) and the PP 
population (b). HAM-D-17, 17-item Hamilton Depression Rating Scale; 
ITT, intention-to-treat; LOCF, last observation carried forward; PP, 
per-protocol; *P < 0.05.
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ITT and PP population (P < 0.05) (Supplementary Fig. 
2, Supplemental digital content 3, http://links.lww.com/
ICP/A72). A summary of primary and secondary efficacy 
outcomes in the ITT and PP populations is presented in 
Table 2.
The severity of disease decreased in both arms from 
moderate to mild, based on the mean MADRS total score 
at the final visit (ITT: trazodone 12.7 ± 8.58, venlafaxine 
10.2 ± 7.02; P = 0.003; PP: trazodone 9.7 ± 6.37, venla-
faxine 8.6 ± 5.40). A statistically significant difference in 
favor of venlafaxine XR was detected in both the ITT 
and PP population (P < 0.05). As already observed with 
the HAM-D-17, the PP population showed the best per-
formance in terms of efficacy outcomes in both groups.
The change in the mean CGI-S score from baseline 
showed a statistically significant difference in favor of 
venlafaxine at the final visit in the ITT but not in the 
PP population. The mean CGI-G score at the final visit 
showed a statistically significant difference in favor of 
venlafaxine both in the ITT and PP population.
The rates of responders with trazodone and venlafaxine 
were 65.4% and 76.3%, respectively, in the ITT popula-
tion (P = 0.0396), and 82.8% and 87.4%, respectively, in 
the PP population (P = 0.2097). The difference in favor 
of venlafaxine was statistically significant in the ITT (P = 
0.0396) but not in the PP population (P = 0.2097).
In the ITT population, clinical remission occurred in 
37.7% and 52.0% of trazodone- and venlafaxine-treated 
patients, respectively (P = 0.0068), while in the PP popu-
lation remission occurred in 48.4% and 60.6% of patients, 
respectively (P = 0.0130). The difference in favor of ven-
lafaxine was statistically significant in both the ITT (P = 
0.0068) and the PP population (P = 0.0130).
Trazodone demonstrated a statistically significant differ-
ence in HAM-D-17 sleep disturbance scores from base-
line in all visits in the PP population (see Supplementary 
Table 1, Supplemental digital content 4, http://links.lww.
com/ICP/A73).
Safety and tolerability
Three hundred and twenty-one patients (165 in the tra-
zodone OAD group and 156 in the venlafaxine XR group) 
who took at least one dose of the study medication were 
included in the safety population.
Table 2 Primary and secondary efficacy outcomes
Outcome at day 56 Trazodone OAD Venlafaxine XR Mean differ-
ence (95% CI)
P value Trazodone OAD Venlafaxine XR Mean difference 
(95% CI)
P value
 ITT population PP Population
Primary efficacy endpoint
HAM-D-17 total score* (n) (n = 162) (n = 152)   (n = 122) (n = 127)   
 Change from baseline [mean (SD)] –12.9 (6.82) –14.7 (6.56) 1.6 (0.4–2.9) 0.010 –15.4 (5.32) –16.4 (5.39) 1.1 (–0.0 to 2.2) 0.056
Secondary efficacy endpoints
MADRS total score (n) (n = 162) (n = 151)   (n = 122) (n = 127)   
 Change from baseline [mean (SD)] –14.4 (7.65) –16.9 (7.65) 2.4 (0.8–4.0) 0.003 –17.1 (6.01) –18.6 (6.58) 1.7 (0.3–3.2) 0.018
CGI-S Total score (n = 162) (n = 152)   (n = 122) (n = 127)   
 Change from baseline [mean (SD)] –1.8 (1.16) –2.1 (1.17)  0.032 –2.1 (1.06) –2.3 (1.02)  0.056
CGI-G total score (n = 162) (n = 152)   (n = 122) (n = 127)   
 Score at day 56 [mean (SD)] 2.0 (1.12) 1.7 (0.99)  0.0088 1.7 (0.82) 1.5 (0.72)  0.0383
HAM-D-17 Response (n = 162) (n = 152)   (n = 122) (n = 127)   
 Responders (50% decrease in 
HAM-D-17 score) [n (%)]
106 (65.4) 116 (76.3)  0.0396 101 (82.8) 111 (87.4)  0.2097
 Remitters (HAM-D-17 total score 
≤ 7) [n (%)]
61 (37.7) 79 (52.0)  0.0068 59 (48.4) 77 (60.6)  0.0130
*Primary efficacy endpoint. Between-group differences were analyzed using ANCOVA, ANOVA or Cochran-Mantel-Haenszel, as appropriate.
CI, confidence interval; CGI-G, Clinical Global Impression of Global Improvement; CGI-S, Clinical Global Impression of Severity; HAM-D-17, 17-item Hamilton Depression 
Rating Scale; ITT, intention-to-treat; LOCF, last observation carried forward; MADRS, Montgomery-Asberg Depression Rating Scale; OAD, once-a-day; PP, per-protocol; 
XR, extended-release.
Table 3 Summary of adverse events in the safety population
Characteristics Trazodone OAD  
(n = 165)
Venlafaxine XR  
(n = 156)
TEAEs   
 Events [n (%)] 161/322 (50.0) 161/322 (50.0)
 Patients [n (%)] 86 (52.1) 73 (46.8)
Related AEs   
 Events [n (%)] 121 (75.2) 133 (82.6)
 Patients [n (%)] 67 (40.6) 63 (40.4)
Most frequent TEAEs [n (%)]   
 Nausea 10 (6.21) 23 (14.29)
 Headache 11 (6.83) 19 (11.80)
 Dizziness 18 (11.18) 6 (3.73)
 Somnolence 14 (8.70) –
Severe AEs   
 Events [n (%)] 2 (1.2) 7 (4.3)
 Patients [n (%)] 2 (1.2) 4 (2.6)
SAEs   
 Events [n (%)] 4 (2.5) 1 (0.6)
 Patients [n (%)] 3* (1.8) 1** (0.6)
AE, adverse event; HAM-D-17, 17-item Hamilton Depression Rating Scale; 
MADRS, Montgomery-Asberg Depression Rating Scale; SAE, serious adverse 
event; OAD, once-a-day; TEAE, treatment-emergent adverse event; XR, 
extended-release.
*One patient had mental impairment and dizziness considered to be related to 
treatment (i.e. certain, probable/likely, possible). All other SAEs were consid-
ered unrelated to treatment (i.e., unlikely, conditional/unclassified, unassessable/
unclassifiable); **Death.
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Three hundred and twenty-two AEs occurred in 159 
patients: 161 AEs in 86 patients receiving trazodone OAD 
and 161 in 73 patients receiving venlafaxine XR. An over-
all summary of AEs is presented in Table  3. The most 
frequent AEs were dizziness (11.18%) and somnolence 
(8.70%) in the trazodone group, and nausea (14.29%) and 
headache (11.80%) in the venlafaxine group. Overall, 
the severity of AEs experienced with both treatments 
was mild-to-moderate in the majority of the cases. Two 
severe AEs occurred in two trazodone-treated patients, 
and seven severe AEs occurred in four patients of the 
venlafaxine group.
Two hundred and fifty-four AEs were judged by the 
investigators as related to the investigational medica-
tions (i.e. certain, probable/likely, possible): 121 AEs in 
67 patients treated with trazodone and 133 AEs in 63 
patients treated with venlafaxine. Five SAEs, including 
one death in the venlafaxine group, occurred during the 
study. They occurred in three patients of the trazodone 
group and one patient of the venlafaxine group (Table 3).
Statistically significant differences between the two treat-
ment groups were found in the changes of ECG param-
eters from the screening at postrandomization visits. At 
the final visit, both groups were significantly different 
in the changes from screening in the following param-
eters: QTcF, QT, RR, and QRS. Eleven patients in the 
trazodone OAD group and six patients in the venlafaxine 
XR group showed QTcF values higher than 450 ms dur-
ing the study or prolongation higher than 60 ms at any 
visit with respect to the screening value. This difference 
between the two treatment groups was not statistically 
significant.
Discussion
The aim of the study was to confirm that trazodone OAD 
is a valid therapeutic option in patients suffering from 
MDD. The efficacy and safety of trazodone were pre-
viously tested vs. venlafaxine in two double-blind stud-
ies, showing comparable efficacy and safety outcomes in 
patients with depressive disorders (Cunningham et al., 
1994; Florkowski et al., 2005).
Patients enrolled, who had moderate-to-severe depres-
sion, showed a significant reduction of depressive symp-
toms in the HAM-D-17 and MADRS total scores at the 
final visit, in both treatment groups.
As required by the EMA guidelines on depression (EMA/
CHMP/185423/2010 Rev. 2, 2013), besides statistically 
significant results, the incorporation of responder/remit-
ter analyses permits the adequate assessment of the clin-
ical relevance of results. In this study, both treatments 
showed high response and remission rates, allowing the 
study results to be defined as robust and clinically mean-
ingful, in accordance with the European guidance.
The venlafaxine group showed greater efficacy in terms 
of the primary and secondary endpoints after 8 weeks, in 
particular considering the responders and remitters’ rates.
As expected, for both drugs, better efficacy outcomes 
were observed in the PP population, which represents 
the study population with the higher level of compliance 
with the study procedure and medication.
Both antidepressants showed good performance com-
pared to the literature data, since the response rate in the 
trazodone and venlafaxine arms were higher than that 
observed with citalopram (47%) after 14 weeks of treat-
ment in the largest ‘real-world’ study on the treatment 
of nonpsychotic depression, the STAR*D trial (Trivedi 
et al., 2006).
From a clinical perspective, both trazodone and venla-
faxine showed a HAM-D-17 total score at the final visit 
comprising between 7 and 17, indicating a reduction of 
the symptoms of depression to within the mild depres-
sion range (Cusin et al., 2010).
The results of this trial confirmed the early onset of action 
of trazodone that was effective after only 7 days of treat-
ment. The early onset of action is a specific characteristic 
of trazodone, previously observed in a placebo-controlled 
study (Sheehan et al., 2009b) and in an observational 
study (Češková et al., 2018). It can be assumed that the 
fast response to trazodone is achieved thanks to the 
combination of SERT inhibition with 5-HT
1A
 receptor 
partial agonism (Montalbano et al., 2019). In a post-hoc 
analysis of the placebo-controlled study that analyzed 
whether the antidepressant response to trazodone OAD 
was associated with an early improvement in insomnia, it 
was confirmed that the antidepressant effect of trazodone 
was robust and largely independent of the known effects 
of trazodone on insomnia (Sheehan et al., 2009a).
Since compliance and treatment adherence are crucial 
aspects of the outcome of MDD treatment, an early 
onset of antidepressant action is clinically important. 
Indeed, antidepressants that lead to a rapid improvement 
of depressive symptoms within a few days, and whose 
effects are sustained in time, would have an important 
impact on public health and on the life of MDD patients 
(Machado-Vieira et al., 2008). A delayed onset of action 
could mean prolonged disability and could lead to an 
increased risk of suicide (Tylee and Walters, 2007). In 
a recent study, it was found that the effect of medica-
tion compliance directly affected the recurrence rate of 
depression (Cheng et al., 2016).
Compared to venlafaxine, trazodone demonstrated a sta-
tistically significant difference in HAM-D-17 sleep dis-
turbance scores in almost all visits in both the ITT and 
PP populations, suggesting its greater efficacy in the treat-
ment of MDD patients experiencing secondary insomnia. 
This is another specific characteristic of trazodone, pre-
viously reported in double-blind placebo-controlled and 
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active-controlled studies (Kasper et al., 2005; Munizza et 
al., 2006). It has been observed that sleep-related dis-
turbances, such as difficulty in initiating or maintaining 
sleep, are often not resolved or even worsened by anti-
depressant treatments. An antidepressant able to reduce 
sleep disturbance in depression may improve the quality 
of life of patients, targeting a symptom that can strongly 
affect depression relapse and recurrence (Nutt et al., 
2008).
In general, reported AEs were as expected and 
mild-to-moderate in severity, and more than 90% of the 
AEs were recovered/resolved at the final visit. The most 
frequent AEs were dizziness and somnolence in the 
trazodone group, and nausea and headache in the ven-
lafaxine group. This finding reflects the different phar-
macological characteristics of trazodone and venlafaxine. 
As expected, both treatments influenced ECG parame-
ters. However, no patients experienced ECG alteration 
judged as ‘abnormal and clinically significant’ across the 
study.
The main limitation of this study is the lack of a placebo 
arm and the wide margin set for defining the noninferi-
ority analysis. However, the results observed in this trial 
confirmed the evidence from comprehensive review of 
the literature that venlafaxine can be considered among 
the most effective antidepressants (Cipriani et al., 2018) 
and reproduced the well-known efficacy and safety pro-
file of trazodone, in particular the early onset of action 
and the positive effect on sleep disturbances, which are 
specific characteristics of the drug.
In conclusion, both trazodone OAD and venlafaxine XR 
proved to be effective antidepressants in patients with 
moderate to severe MDD. Trazodone OAD was shown 
to achieve an early response and good efficacy on sleep 
parameters, although venlafaxine XR was more effec-
tive than trazodone OAD in terms of per responder and 
remitter rates, confirming data from the literature show-
ing that it may be superior to conventional antidepres-
sants in severe depression.
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